Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib (FT-2102) in IDH1-Mutant Solid Tumors and Gliomas
NCT03684811Phase 2Completed
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Nov 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of olutasidenib in glioma, hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) and 2 more (4 arms), sponsored by Forma Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicity and Overall Response Rate. Started Nov 2018; status: completed.
02
Drugs
olutasidenib
03
Conditions
gliomahepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)chondrosarcomasolid tumor
Beyond the preview
Go deeper on NCT03684811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684811.